Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Hadasit Launches New Jewish-Arab Biomedical Community Initiative

hMediciine

Hadasit, the Hadassah University Medical Center's technology transfer company, has launched an incubator for joint Jewish-Arab biomedical ventures in northern Israel entitled WAYS—an acronym based on the names of its founders.

WAYS was created by Yaron Bar-Ilan, an entrepreneur who will serve as its Chief Executive Officer; Dr. Yaron Lev-Or, a biotechnology entrepreneur; Prof. Yaron Ilan, head of Internal Medicine Department A at Hadassah; and Wafa Laham, an Arab businesswoman from Nazareth. Supported by a group of investors and business people from the region, WAYS initially aims to support 12 biotechnology projects with a grant of $500,000-$1,000,000 each.

In addition to joint Jewish-Arab biotechnology ventures, WAYS will foster entrepreneurship among new immigrants and outstanding teenagers from the region. It is expected that 7.5 million shekels will be invested in WAYS over the next five years. Several million dollars have already been pledged to WAYS from social organizations.
WAYS will help its portfolio companies become commercial companies, based in the Jezreel Valley and Lower Galilee. It will encourage young Arab physicians and new immigrants in northern Israel to become entrepreneurs while providing a professional response to the various challenges they face.
Hadasit Chief Executive Officer Dr. Einat Zisman notes, "WAYS is a unique first-of-its kind-venture to foster life sciences and drug development companies through social activity from different sectors of the population. Hadassah is proud to be part of this pioneering initiative."

Date: 9/12/2011


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America